Optimizing cisplatin delivery to triple-negative breast cancer through novel EGFR aptamer-conjugated polymeric nanovectors

Optimizing cisplatin delivery to triple-negative breast cancer through novel EGFR aptamer-conjugated polymeric nanovectors

Abstract Background Management of triple-negative breast cancer (TNBC) is still challenging because of its aggressive clinical behavior and limited targeted treatment options. Cisplatin represents a promising chemotherapeutic compound in neoadjuvant approaches and in the metastatic setting, but its...

Full description

Bibliographic Details
Main Authors: Lisa Agnello, Silvia Tortorella, Annachiara d’Argenio, Clarissa Carbone, Simona Camorani, Erica Locatelli, Luigi Auletta, Domenico Sorrentino, Monica Fedele, Antonella Zannetti, Mauro Comes Franchini, Laura Cerchia
Format: Article
Language:English
Published: BMC 2021-07-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Aptamer
Cancer targeting
EGFR
Enhanced therapeutic effects
Nanomedicine
Targeted drug delivery
Online Access:https://doi.org/10.1186/s13046-021-02039-w

Internet

https://doi.org/10.1186/s13046-021-02039-w

Similar Items